In this study, we demonstrated that chelidonine treatment reduced FOXM1 and PLK1 expression, which implied that chelidonine may inhibit proliferation of BC cells by inhibiting the AKT/FOXO3/FOXM1 pathway. The gene discussed is FOXM1; the disease is breast cancer.